{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/raynauds-phenomenon/management/management/","result":{"pageContext":{"chapter":{"id":"f6006983-20db-5702-8a8c-9763d45ab3cf","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field ebebc5be-d685-41fc-9992-ec06f0f65942 --><h2>Scenario: Management of Raynaud's phenomenon</h2><!-- end field ebebc5be-d685-41fc-9992-ec06f0f65942 -->","summary":"Covers the management of people with Raynaud's phenomenon.","htmlStringContent":"<!-- begin item c352675c-3fc5-40be-8cf5-b622a32beaa6 --><!-- begin field 97a5d53e-c56d-48bf-bd5f-acbc01573fe4 --><p>From age 5 years onwards.</p><!-- end field 97a5d53e-c56d-48bf-bd5f-acbc01573fe4 --><!-- end item c352675c-3fc5-40be-8cf5-b622a32beaa6 -->","topic":{"id":"255ee7a1-48e0-54c2-a732-4e03fba17a60","topicId":"e0f3a627-69e7-4258-bfd3-06ad68e3ba94","topicName":"Raynaud's phenomenon","slug":"raynauds-phenomenon","lastRevised":"Last revised in February 2020","chapters":[{"id":"0209e319-b6f4-5f73-ae5c-6afd753453ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9bb70ded-aa7a-5909-9d84-111f559bccc8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"47c14b87-688e-5e8e-af1c-e6614c461561","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ad9e53ac-9556-5bdd-aa04-09e22fccd689","slug":"changes","fullItemName":"Changes"},{"id":"aa95064f-a6c4-5317-a6ec-33fca3665fa5","slug":"update","fullItemName":"Update"}]},{"id":"0346daa7-fb38-5512-b2c8-7f0d5d4b7c91","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"074b9165-8cc3-56b5-a9fa-483516a026aa","slug":"goals","fullItemName":"Goals"},{"id":"dadcf48d-9a98-54cf-baab-c0b65179b8f1","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d272b294-ed60-5488-8640-d756cbe670a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9dcdeaed-4201-583c-a5a9-5dcb4ead9acb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c107602-0bb8-52d9-b277-5639494a105e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72ac11d0-1027-5c50-ae82-9ae1e1bf92b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0559a1bc-62df-54ef-846b-db71b06fbe87","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2ec7ca08-f644-50e8-b54e-c6378c7053b0","slug":"definition","fullItemName":"Definition"},{"id":"951db58c-3bcb-56ef-be5f-1e0fd9fdbd81","slug":"causes-of-or-diseases-associated-with-raynauds-phenomenon","fullItemName":"Causes of, or diseases associated with Raynaud's phenomenon:"},{"id":"b9b9e063-b592-5419-8f15-8f350c8de255","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"16789ea7-d3e6-5c24-a51f-e9f57845b88b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b914d639-5ff2-526f-86e9-1280331ece9b","slug":"complications","fullItemName":"Complications"}]},{"id":"1478d9b3-2ba3-5103-9fab-2a67d58f88f4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"509776f6-588e-5896-9432-bf45ef2f63e1","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a10980a-a167-52bd-9991-be6f6cd68c50","slug":"assessment","fullItemName":"Assessment"},{"id":"ab1aab22-cf2f-584c-b073-a5bba7ae4c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"143745f3-74bd-57da-b042-3dd311837d98","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6006983-20db-5702-8a8c-9763d45ab3cf","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ede08fed-d06c-5c6c-9c34-9ada648e6c09","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1c7cb268-2a82-5737-b0ee-332487a61ea1","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"f6403106-c5ec-5705-bdcf-a225c5de60f9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8a93fc9c-f20c-58a4-a5db-33420cd3b27a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e2a1391d-6c3d-5d36-b072-abc59f16980c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"bfa3b4f4-feec-59d7-9574-f36fc1bcf5cd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"18ed7dfb-e0e7-5be9-9a57-0ab24f1666c5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2bf5741c-d447-5f96-8155-861976265e79","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"52d565ac-2dac-556a-9bc8-c5c8946df2ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1b7e64ea-3359-5d63-93ff-6b661619a25e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"143745f3-74bd-57da-b042-3dd311837d98","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"92123fbc-335d-51a9-871c-d65bcd8be7d3","slug":"management-of-raynauds-phenomenon","fullItemName":"Management of Raynaud's phenomenon","depth":3,"htmlHeader":"<!-- begin field fd2736b7-58cc-4265-adcf-7aacd4342d12 --><h3>How should I manage Raynaud's phenomenon?</h3><!-- end field fd2736b7-58cc-4265-adcf-7aacd4342d12 -->","summary":null,"htmlStringContent":"<!-- begin item 6b93e8d9-5f5b-4df9-b3e7-db5b2e395bcb --><!-- begin field 8bdc0e18-fcd2-473c-8293-833bfb85225b --><ul><li><strong>Arrange immediate admission if:</strong><ul><li>The person has severe ischaemia of one or more digits.</li></ul></li><li><strong>Refer to rheumatology:</strong><ul><li>All people with suspected <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/diagnosis/clinical-features/\">secondary Raynaud&#39;s phenomenon</a>.<ul><li>If an occupational cause is suspected, refer to an occupational medicine specialist or vascular clinician with expertise in this area (depending on local protocol).</li></ul></li><li>All children aged 12 years or younger with Raynaud's phenomenon.</li><li>If symptoms are worsening, severe or unresponsive to standard treatment.</li></ul></li><li><strong>If a <a class=\"topic-reference internal-reference\" href=\"/topics/raynauds-phenomenon/background-information/causes-of-or-diseases-associated-with-raynauds-phenomenon/\">drug</a> may be causing or exacerbating the Raynaud's phenomenon, review the need for it and, if possible, stop it.</strong></li><li><strong>Advise the following lifestyle measures for all people with Raynaud's phenomenon:</strong><ul><li>Keep the <em>whole</em> body (including the hands and feet) warm:<ul><li>Avoid sudden temperature changes.</li><li>Do not allow the hands and feet to get cold.</li><li>Wear gloves and warm footwear in cold environments.</li><li>Consider using hand and foot warming devices — information available from the <a data-hyperlink-id=\"6c4bb3fd-5646-4f65-9408-ab5f00b26772\" href=\"https://www.sruk.co.uk/\" target=\"_blank\">Scleroderma and Raynaud’s UK</a> website.</li></ul></li><li>Avoid or stop smoking — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li>Try to minimize stress if this is a trigger.</li><li>Exercise regularly.</li></ul></li><li><strong>Provide patient information on Raynaud's phenomenon such as:</strong><ul><li><a data-hyperlink-id=\"5ea0533a-b570-4e58-802a-ab5f00b267a8\" href=\"https://www.nhs.uk/conditions/raynauds/\" target=\"_blank\">NHS Choices Raynaud’s</a>.</li><li><a data-hyperlink-id=\"ee679955-1a50-460d-9ce8-ab5f00b267bf\" href=\"https://www.sruk.co.uk/\" target=\"_blank\">Scleroderma and Raynaud’s UK</a>.</li></ul></li><li><strong>If lifestyle measures fail and symptoms are having a significant negative impact, consider a trial of nifedipine as prophylaxis.</strong><ul><li>The decision to treat should be determined by the frequency and severity of attacks and the person's preference.</li><li>For young people aged 13 to 17 years, seek specialist advice regarding treatment.</li><li>For adults 18 years of age or older, consider either:<ul><li>An immediate-release preparation (licensed use, but associated with more adverse effects) initially 5 mg three times a day, then adjust slowly according to response up to 20 mg three times a day, <em>or</em></li><li>A modified-release preparation (<em>off-label use</em>, but may have fewer adverse effects) initially 10 mg once daily, adjusted slowly according to response up to 60mg a day.</li></ul></li><li>Advise that up to three-quarters of people have adverse effects, such as oedema, palpitations, headache, flushing, or dizziness.<ul><li>If nifedipine is not tolerated, consider prescribing another calcium-channel blocker, such as amlodipine (<em>off-label use</em>).</li></ul></li><li>Intermittent prophylactic use (in cold weather or when participating in outdoor winter activities) may be sufficient.</li><li>In people with primary Raynaud's phenomenon, consider periodically stopping treatment as the disease may go into remission.</li></ul></li><li><strong>Refer people with symptoms that are poorly controlled or worsening despite appropriate treatment</strong>.</li></ul><!-- end field 8bdc0e18-fcd2-473c-8293-833bfb85225b --><!-- end item 6b93e8d9-5f5b-4df9-b3e7-db5b2e395bcb -->","subChapters":[{"id":"c6130298-12e7-5256-81ec-e766ac0b38a0","slug":"basis-for-recommendation-54e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 13cb2a64-01a6-41e4-ac3e-f6c3ff051bdc --><h4>Basis for recommendation</h4><!-- end field 13cb2a64-01a6-41e4-ac3e-f6c3ff051bdc -->","summary":null,"htmlStringContent":"<!-- begin item 54e7de33-e0da-48eb-8e0e-5f03548fa21e --><!-- begin field d83fa6bb-9d77-40f2-b1bd-429ccc5fc4de --><p>The recommendations on the management of Raynaud’s phenomenon are based on clinical guidelines <em>Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>] and <em>European Society for Vascular Medicine (ESVM) guidelines - the diagnosis and management of Raynaud's phenomenon </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>], expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Butendieck, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Wigley, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Shapiro, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hinze, 2018</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">BNF, 2019</a>].</p><h5>Admission and referral</h5><p>The recommendations on when to admit or refer a person with Raynaud’s phenomenon are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Pain, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Shapiro, 2017</a>].</p><ul><li>Critical ischaemia — early recognition and prompt treatment is essential to prevent critically ischaemic digits from becoming unviable [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li><li>Secondary Raynaud's phenomenon — most people seen in primary care will have primary Raynaud’s phenomenon, however, it is important to be alert for any symptoms, signs or blood tests that raise suspicion of secondary Raynaud's phenomenon. Missing a connective tissue disease or other associated causes can have serious consequences therefore prompt referral to secondary care is indicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Shapiro, 2017</a>].</li><li>Worsening symptoms — Raynaud's phenomenon can precede connective tissue disease by many years, worsening symptoms should trigger referral to rheumatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li><li>Raynaud's phenomenon in children — primary Raynaud’s phenomenon is less common in younger age groups and can be the presenting feature of juvenile systemic sclerosis, juvenile systemic lupus erythematosus or other connective tissue disease. Referral for further assessment is recommended in clinical guidance from the European Society for Vascular Medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and the Paediatric Rheumatology European Society Juvenile Scleroderma Working Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Pain, 2016</a>].<ul><li>Raynaud’s phenomenon has been reported as the first sign of disease in 61–70% of children with juvenile systemic sclerosis, 58% of children with mixed connective tissue disease, and 16% of children with juvenile dermatomyositis — early identification and specialist management is essential to minimise later complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Pain, 2016</a>].</li></ul></li></ul><h5>Withdrawal of drugs that may cause or exacerbate Raynaud’s phenomenon</h5><ul><li>The recommendation on consideration of withdrawal of vasoconstrictor drugs is from clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li></ul><h5>Advice on self-care/lifestyle measures</h5><ul><li>It is widely agreed in clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Ennis, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Wigley, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Shapiro, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hinze, 2018</a>] that education on lifestyle measures and avoidance of triggers are a first line strategy in the management of Raynaud’s phenomenon.</li></ul><h5>Drug treatment</h5><p>Recommendations on drug treatment of Raynaud’s phenomenon are based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Butendieck, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hughes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Hinze, 2018</a>] which agree that drug treatment can be considered where lifestyle measures have failed and symptoms are having a significant impact on activities of daily life.</p><ul><li>Calcium channel blockers are widely used and recommended as first-line drug treatment for Raynaud’s phenomenon despite relatively limited and variable evidence on efficacy and safety [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Herrick, 2017</a>].<ul><li>A Cochrane review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Ennis, 2016</a>] of calcium channel blockers for primary Raynaud’s phenomenon (7 randomized trials, n=296) found that calcium channel blockers reduced frequency of attacks by 1.72 (95 % CI 0.60 to 2.84) per person per week compared to placebo. Reported adverse effects included headaches, flushing and ankle swelling. The authors concluded that oral calcium channel blockers are minimally effective in the treatment of primary Raynaud's phenomenon and have little effect on severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li><li>A meta‐analysis (18 trials) of calcium channel blockers in the treatment of primary Raynaud's phenomenon reported efficacy as small with a reduction in frequency of attacks from 2.8–5.0 per week and a reduction in severity of 33% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Thompson and Pope, 2005</a>].</li><li>A meta-analysis (11 studies, n=361) of secondary Raynaud’s phenomenon (related to systemic sclerosis) reported that treatment with calcium channel blockers led to a mean reduction in attacks of 8.3 in 2 weeks and 35% less severity compared to placeboa; the authors concluded that calcium-channel blockers were moderately effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Thompson, 2001</a>].</li><li>A Cochrane review (38 randomized controlled trials, n=982) of use of calcium channel blockers in the treatment of primary and secondary Raynaud’s phenomenon found that calcium channel blockers reduced the number of attacks on average by 6 per week compared to placebo when taken for 2 to 20 weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Rirash, 2017</a>].</li></ul></li><li>Only immediate release preparations of nifedipine are licenced for use in Raynauds phenomenon [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">BNF, 2019</a>]. The recommendation on use of longer acting preparations is based on a clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>] which states that longer acting formulations are often preferred as short acting preparations are more likely to have vasodilatory adverse effects and their action lasts only a few hours.</li><li>Treatment of primary Raynaud’s phenomenon with other vasodilators is not recommended due to a lack of evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/raynauds-phenomenon/references/\">Belch, 2017</a>].</li></ul><!-- end field d83fa6bb-9d77-40f2-b1bd-429ccc5fc4de --><!-- end item 54e7de33-e0da-48eb-8e0e-5f03548fa21e -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}